GATTEX ONE-VIAL (teduglutide)
SHORT BOWEL SYNDROME-GLUCAGON-LIKE PEPTIDE-2 (GLP-2) ANALOG · SHORT BOWEL SYNDROME
MILLENNIUM PHAR
Drug class
Short Bowel Syndrome-glucagon-like peptide-2 (GLP-2) analog
The classification "Short Bowel Syndrome-glucagon-like peptide-2 (GLP-2) analog" is a compendial and clinical drug category encompassing synthetic peptide analogs of naturally occurring GLP-2. Read more about Short Bowel Syndrome-glucagon-like peptide-2 (GLP-2) analog
4 drugs in this class 2 manufacturers
Drugs in Short Bowel Syndrome-glucagon-like peptide-2 (GLP-2) analog
GATTEX 30-VIAL (teduglutide)
SHORT BOWEL SYNDROME-GLUCAGON-LIKE PEPTIDE-2 (GLP-2) ANALOG · SHORT BOWEL SYNDROME
MILLENNIUM PHAR
GATTEX (teduglutide)
SHORT BOWEL SYNDROME-GLUCAGON-LIKE PEPTIDE-2 (GLP-2) ANALOG · SHORT BOWEL SYNDROME
MILLENNIUM PHAR
GATTEX (teduglutide)
SHORT BOWEL SYNDROME-GLUCAGON-LIKE PEPTIDE-2 (GLP-2) ANALOG · SHORT BOWEL SYNDROME
Takeda Pharmaceuticals America
Filter & compare in the drug finder →
Opens the drug finder with Short Bowel Syndrome-glucagon-like peptide-2 (GLP-2) analog preselected. Add indication or manufacturer filters there.
The classification "Short Bowel Syndrome-glucagon-like peptide-2 (GLP-2) analog" is a compendial and clinical drug category encompassing synthetic peptide analogs of naturally occurring GLP-2.
Agents in this class, such as teduglutide, act as intestinal trophic factors by selectively binding and activating GLP-2 receptors to stimulate mucosal growth, increase intestinal villus height and crypt depth, and enhance gastrointestinal blood flow.
These pharmacodynamic effects significantly increase fluid and nutrient absorption in the remnant intestine.
The therapeutic class is indicated specifically for the treatment of short bowel syndrome in patients dependent on parenteral nutrition or intravenous fluid support, serving to reduce or eliminate the need for ongoing parenteral intervention.
-
connectrx.com
The classification "Short Bowel Syndrome-glucagon-like peptide-2 (GLP-2) analog" is a compendial and clinical drug category encompassing synthetic peptide analogs of naturally occurring GLP-2 Agents in this class, such as teduglutide, act as intestinal trophic factors by selectively binding and activating GLP-2 receptors to stimulate mucosal growth, increase intestinal villus height and crypt depth, and enhance gastrointestinal blood flow
-
nih.gov
The classification "Short Bowel Syndrome-glucagon-like peptide-2 (GLP-2) analog" is a compendial and clinical drug category encompassing synthetic peptide analogs of naturally occurring GLP-2 Agents in this class, such as teduglutide, act as intestinal trophic factors by selectively binding and activating GLP-2 receptors to stimulate mucosal growth, increase intestinal villus height and crypt depth, and enhance gastrointestinal blood flow These pharmacodynamic effects significantly increase flui...
-
nih.gov
Agents in this class, such as teduglutide, act as intestinal trophic factors by selectively binding and activating GLP-2 receptors to stimulate mucosal growth, increase intestinal villus height and crypt depth, and enhance gastrointestinal blood flow These pharmacodynamic effects significantly increase fluid and nutrient absorption in the remnant intestine The therapeutic class is indicated specifically for the treatment of short bowel syndrome in patients dependent on parenteral nutrition or in...
-
nih.gov
The therapeutic class is indicated specifically for the treatment of short bowel syndrome in patients dependent on parenteral nutrition or intravenous fluid support, serving to reduce or eliminate the need for ongoing parenteral intervention
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.